IBCSG 54-16 METEORA-II

  • A randomized phase II trial of metronomic oral vinorelbine  plus cyclo­phos­phamide and capecitabine (VEX) versus weekly paclitaxel as first-line or second-line treatment in patients with ER-positive/HER2-negative advanced or metastatic breast cancer

  • Study Chair
    Dr. Elisabetta Munzone (IEO Milan, Italy)

    Statistician
    Meredith M. Regan, ScD

    Trial contact in Italy:
    Raffaella Ghisini, MSc

    Data Manager
    Dorene Polizzi 

    Trial Coordinator
    Dorene Polizzi

    IBCSG Data Management Center/Frontier Science Foundation
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    February 13, 2017 

    Final Accrual
    140 

    Accrual Closure Date
    January 31, 2022

    Global Trial completion date
    April 20, 2023

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login